Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 8/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL7365687 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNAGRNSORT1MMP2 | |
| Leucine SCHEMBL6418640 | 0.89 | SLC7A5 (0.44) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL7367908 | 0.89 | SLC7A5 (0.44) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL6416175 | 0.89 | MMP2 (0.47) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL7364033 | 0.89 | SLC7A5 (0.44) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL6411762 | 0.89 | SLC7A5 (0.44) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL7318515 | 0.89 | MMP2 (0.47) | MMP2MMP3MMP1SLC7A5MME | |
| Leucine SCHEMBL6412971 | 0.89 | MMP2 (0.50) | MMP2MMP3MMP1MMEACE | |
| Leucine SCHEMBL7319680 | 0.84 | MMP2 (0.61) | ALDH1A1MMP2MMP3MMP1SLC7A5 | |
| Leucine SCHEMBL7382855 | 0.83 | LMNA (0.45) | ALDH1A1LMNAGRNSORT1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5932551-A | INHIBITORS OF MATRIX METALLOENDOPROTEINASE-MEDIATED DISEASES | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | claimed |
| WO-1992021360-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO., INC. (US) | 1992-12-10 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5932551-A | INHIBITORS OF MATRIX METALLOENDOPROTEINASE-MEDIATED DISEASES | MERCK & CO., INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0586537-A4 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO INC (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0586537-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO. INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021360-A1 | SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS | MERCK & CO., INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ALDH1A1 1814/4885LMNA 1874/4885GRN 1201/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ALDH1A1 1814/4885LMNA 1874/4885GRN 1201/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ALDH1A1 1814/4885LMNA 1874/4885GRN 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.